Urology
Volume 79, Issue 2 , Pages 458-463, February 2012

I-Stop TOMS Transobturator Male Sling, a Minimally Invasive Treatment for Post-prostatectomy Incontinence: Continence Improvement and Tolerability

  • Philippe Grise

      Affiliations

    • Department of Urology, Rouen University Hospital, Rouen, France
    • Corresponding Author InformationReprint requests: Philippe Grise, M.D., Department of Urology, Rouen University Hospital, 1 Rue de Germont, 76038 Rouen cedex, France
  • ,
  • Renaud Vautherin

      Affiliations

    • Department of Urology, Trenel Clinic, Sainte-Colombe, France
  • ,
  • Bertin Njinou-Ngninkeu

      Affiliations

    • Ormeaux Clinic, Le Havre, France
  • ,
  • Ghislain Bochereau

      Affiliations

    • Saint Augustin Clinic, Nantes, France
  • ,
  • Jean Lienhart

      Affiliations

    • Department of Urology, Trenel Clinic, Sainte-Colombe, France
  • ,
  • Christian Saussine

      Affiliations

    • Department of Urology, Strasbourg University Hospital, Strasbourg, France
  • ,
  • HOMme INContinence Study Group

      Affiliations

    • A complete list of the HOMme INContinence Study Group can be found in the Appendix.

Received 31 May 2011; accepted 26 August 2011. published online 20 December 2011.

Objective

To prospectively evaluate the efficacy and tolerability of the I-STOP TOMS transobturator male sling in patients with post-prostatectomy stress urinary incontinence. Minimally invasive techniques, such as slings, are becoming the standard of care for mild to moderate post-prostatectomy incontinence.

Methods

From March 2007 to June 2009, 122 patients with post-prostatectomy stress urinary incontinence were treated with the I-STOP TOMS sling and followed up for 1 year in the Phase IV HOMme INContinence trial. The preoperative and postoperative evaluation included daily pad use, pad test, questionnaires evaluating urinary function and bother (University of California, Los Angeles, Prostate Cancer Index – urinary function short form, and International Consultation on Incontinence Modular Questionnaire – urinary incontinence short form) and uroflowmetry, including the post-void residual urine volume. Patient satisfaction and perineal pain were also assessed.

Results

A total of 103 patients were followed up for 12 months. The surgical procedure was considered easy to perform. The mean daily pad use decreased significantly from 2.4 to 0.6 at 12 months of follow-up; 87.0% of the patients reported improved continence (59.4% completely dry, 20.3% 1 pad/d, 7.3% >1 pad/d), and 13.0% reported no improvement. All quality-of-life scores (University of California, Los Angeles, Prostate Cancer Index – urinary function short form, and International Consultation on Incontinence Modular Questionnaire – urinary incontinence short form) improved significantly after sling implantation. Treatment satisfaction was >90%. The post-void residual urine volume did not increase substantially, and acute urinary retention did not occur. The perineal pain scores were very low at follow-up. Wound infection was seen in 2 patients at the 1-month follow-up visit.

Conclusion

The I-STOP TOMS is a good treatment option for patients with post-prostatectomy stress urinary incontinence. With follow-up ≤12 months, most patients were continent or had improved continence. The intervention was well tolerated, with few infections.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial Support: CL Medical provided an unconditional grant to support the writing of our report.

 Financial Disclosure: P. Grise is an investigator for Ipsen, Medtronic, and CL Medical; and C. Saussine is an investigator for CL Medical and a consultant for Allergan, AMS, CL Medical, Coloplast, GSK, and Ipsen.

PII: S0090-4295(11)02527-1

doi:10.1016/j.urology.2011.08.078

Urology
Volume 79, Issue 2 , Pages 458-463, February 2012